Drug intelligence / Profile preview

NGX-1998

Development stage: Phase 2
Lead developer: NeurogesX
Modality: Small Molecules
Administration: Topical

Overview

NGX-1998 is a topically applied, high-concentration liquid formulation of capsaicin designed to treat pain associated with neuropathic pain conditions, such as postherpetic neuralgia (PHN). It is developed by NeurogesX, Inc. and aims to provide rapid delivery of capsaicin into the skin, potentially offering shorter treatment times compared to existing capsaicin patches like Qutenza.

Other names: capsaicin 10% solutioncapsaicin 20% solutioncapsaicin liquid formulation

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on NGX-1998.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGX-1998.

Explore the full profile